Paris (ots/PRNewswire) – – For The First Time: Direct Link Found Between Reducing Heart Rate and Quality of Life New results from SHIFT (Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial), the largest-ever morbi-mortality study of treatments for chronic heart failure, reveal for the first time a direct link between heart rate reduction [...]
Tag Archive > European Society Of Cardiology
Largest Atrial Fibrillation Registry Reveals Poor AF Control and High Rates of Cardiovascular Hospitalization
Paris (ots/PRNewswire) – Sanofi-aventis announced today that results from the RealiseAF (Real-life global survey evaluating patients with Atrial Fibrillation) registry show that control of atrial fibrillation (AF) (defined by the 2006 ACC/AHA/ESC AF guidelines as either sinus rhythm or AF with heart rate at rest less than or equal 80 bpm)[1] was not achieved in [...]
Pitavastatin Demonstrates no Significant Drug-to-Drug Interaction When Administered With CYP3A4 Inhibitors
Barcelona, Spain (ots/PRNewswire) – – Data Shows Potential Tolerability Advantage for Pitavastatin Compared With Other Statins New data presented at the European Society of Cardiology congress (ESC) demonstrated that the co-administration of the cytochrome inhibitor itraconazole has no clinically relevant effect on the pharmacokinetics of pitavastatin, in healthy volunteers. Many of the existing statins such [...]
New Insights Link Low HDL-Cholesterol and Elevated Triglycerides With Coronary Heart Disease and Microvascular Complications in Patients at Goal for LDL-Cholesterol
Barcelona (ots/PRNewswire) – – Surveys Establish Residual Vascular Risk is Associated With Atherogenic Dyslipidemia Suggesting the Need to Reconsider Approach to Management of Lipids – Residual Risk Reduction initiative (R3i) Foundation Presents Early Findings From Unique Global Investigation Into Effects on Residual Macrovascular and Microvascular Risk Low levels of high-density lipoprotein cholesterol (HDL-C) and raised [...]
Pitavastatin is Non-Inferior to Atorvastatin and Simvastatin and Demonstrates Sustained Efficacy and Tolerability Over 52 Weeks
Barcelona, Spain (ots/PRNewswire) – – Pitavastatin Represents Long-Term Treatment Option for Patients With Primary Hypercholesterolaemia or Combined Dyslipidaemia New phase III data presented at the European Society of Cardiology congress (ESC) demonstrated that pitavastatin is non-inferior to atorvastatin and simvastatin at usual therapeutic doses in patients with primary hypercholesterolemia or combined dyslipidemia, as measured by [...]
Eight out of 10 People Diagnosed With Heart Disease Consider Their Diagnosis a ‘Wake-Up Call’
Barcelona, Spain (ots/PRNewswire) – – Your Heart: New Start initiative launched to provide heart patients and their carers with information about nutrition, fitness and medication adherence Eight out of 10 heart patients in an international survey of more than 3,000 patients felt their heart disease diagnosis was a wake-up call to live a healthier lifestyle. [...]
In Heart Failure Patients Treated With ACE Inhibitor and/or Beta Blocker, Higher Plasma Renin Activity is Related to Greater Risk of Mortality
Basel, Switzerland (ots/PRNewswire) – – New Analysis of Data From landmark ‘Valsartan Heart Failure Trial’ Adds to Growing Evidence That Plasma Renin Activity (PRA) is Linked to Cardiovascular Outcomes (1-3) – PRA is a Measure of the Activity of the Renin Angiotensin System (RAS) – The Only High Blood Pressure Treatment That Blocks the RAS [...]
Abbott Launches Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in International Markets
Barcelona, Spain (ots/PRNewswire) – – New Cobalt Chromium Stent Offers Enhanced Deliverability with a Broad Matrix of Sizes – Built Upon the Proven Track Record of Superior Clinical Outcomes of Abbott’s Market-Leading XIENCE V(R) Drug Eluting Stent Abbott (NYSE: ABT) today announced at the European Society of Cardiology Congress the widespread availability of its next-generation [...]
Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
Paris (ots/PRNewswire) – – SEPIA-ACS Multiple-dose Phase II Results Showing 27- 42% Risk Reduction in ACS Complications Presented in Plenary Session of European Society of Cardiology Congress and Published in The Lancet Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational anti-Xa intravenous anticoagulant otamixaban reduced by 27 to 42 percent the odds [...]
New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of PLAVIX(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty
Paris, and Princeton, New Jersey (ots/PRNewswire) – -No added benefit on the composite primary end-point with the higher dose when entire ACS study population considered- -Important new findings with higher loading dose of PLAVIX(R) for heart patients undergoing coronary angioplasty (PCI)- Today, the OASIS study group will present initial results of the CURRENT-OASIS 7 clinical [...]
